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Abstract: Duchenne muscular dystrophy (DMD) and murine X-linked muscular dystrophy (mdx), its murine
model,  are characterized by muscle damage and muscle weakness associated with inflammation and new vessel
formation. Caveolins, dystrophin-associated proteins, are involved in the pathogenesis of DMD, because in-
creased numbers of caveolae are found in DMD and mdx hindlimb muscles. Caveolae influence angiogenesis
due to their content of vascular endothelial growth factor (VEGF) receptors. Orofacial muscles in mdx mice
undergo muscle necrosis followed by muscle regeneration. To ascertain the role of caveolins and VEGF in the
pathogenesis of dystrophic masticatory muscles, we examined the expression of caveolin-1 (cav-1), caveolin-3
(cav-3) and VEGF in control and mdx mice. In mdx masticatory muscles, no changes in transcript and protein
levels of VEGF were found, whereas cav-1 and cav-3 expression was increased. Using immunohistochemistry,
a strong sarcolemmal staining of caveolin-3 in regenerated muscle fibers was found. Furthermore, immunohis-
tochemistry with the caveolin-1 antibody showed an increase in the amount of blood vessels in areas with regen-
erating muscle fibers. Dystrophic masticatory muscles showed changes comparable to those of hindlimb muscles
in the expression of cav-1 and cav-3. The angiogenesis seems to be unaffected in the jaw muscles of mdx mice.
We speculate that the increased caveolin expression could cause extensive and efficient muscle regeneration.
(Folia Histochemica et Cytobiologica 2011; Vol. 49, No. 2, pp. 291–298)
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Introduction
Caveolae are vesicular invaginations of the plasma
membrane and transport molecules across the endot-
helial barrier. Caveolae are also involved in phagocy-
tosis, signal transduction regulation and cholesterol
transport [1]. Caveolins, a gene family of 21–25 kDa
integral membrane proteins, are the main protein
components of caveolae membranes. The mammali-
an caveolin gene family consists of three different iso-
forms: caveolin1-3 [1]. Caveolin-1 and caveolin-2 are
usually expressed in the same cell type, like adipo-
cytes, endothelial cells and type I pneumocytes [2].
Caveolin-1 is able to bind several proteins via strong-
ly hydrophobic scaffolding domains [3] and regulates
important functions such as angiogenesis, vascular
permeability and transcytosis [4, 5]. In a recent study
on caveolin-deficient mice, angiogenesis was found
to be markedly reduced in comparison with control
mice [6]. Caveolin-3 (cav-3) is present in all muscle
cell types and is the major caveolar protein of differ-
entiated skeletal muscle cells, but it is also expressed
in astrocytes and chondrocytes [7–9]. In skeletal mus-
cle, cav-3 is transiently associated with T-tubules dur-
ing development [10]. Immunohistochemistry of cav-3
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in muscle fibers reveals a co-localization of this protein
with dystrophin at the sarcolemma [11]. Furthermore, cav-3
defects have been closely tied to muscular dystrophy [12].
Mutation in the cav-3 gene causes autosomal dominant
muscle diseases [13, 14]. Transgenic overexpression of
cav-3 has been found to induce a phenotype similar to
Duchenne muscular dystrophy (DMD) [15].
Murine X-linked muscular dystrophy (mdx) and
Duchenne muscular dystrophy (DMD) are charac-
terized by a complete lack of dystrophin [16, 17].
Dystrophin deficiency leads to necrosis of muscle fi-
bers, muscle damage, fibrosis and progressive mus-
cle weakness [18]. Recent studies have identified
a characteristic increase in the number of caveolae in
DMD patients and mdx mice [19–21] and an increase
in the expression of cav-3 levels in DMD and mdx
hindlimb muscles [21, 22].
Beside caveolins, caveolae contain receptors for
key regulators of vascular permeability, the vascular
endothelial growth factors (VEGFs). VEGFA acti-
vates vascular permeability, vasodilatation and new
vessel formation [23]. VEGF can be generated by al-
most all cells under hypoxic conditions and are high-
ly expressed in tissues undergoing growth [24]. Re-
cently it has been shown that cav-1 expression corre-
lates positively with VEGF expression [25] and cav-1
plays multiple roles in the VEGF-induced signaling cas-
cade [26]. Because of the interactions of caveolins with
VEGF, changes in the abundance of caveolins are likely
to influence inflammation and angiogenic processes
in the dystrophic muscles of mdx mice. Caveolins have
been intensively investigated in smooth and limb skel-
etal muscles, but until now little attention has been paid
to their abundance in muscles of the head and neck
region. However, orofacial muscles are constantly load-
ed under important physiological conditions such as
eating, swallowing and breathing, and muscle diseases
may seriously impact these functions.
Recently, it has been shown that the masticatory
muscles of mdx mice are characterized by typical cy-
cles of necrosis and regeneration associated with in-
flammation, muscle fiber hypertrophy and collagen
accumulation [27].
The objective of this study was therefore to ana-
lyze the expression of cav-1, cav-3 and VEGF in the
tongue, masseter and temporal muscles, and one limb
skeletal muscle in 100 day-old mdx mice in order to
examine their potential roles in the regeneration of
masticatory muscles. At this age, in mdx mice, the
regeneration process overwhelms degeneration. Lit-
erature is scarce regarding the caveolin expression
within newly regenerated fibers. Our results could
provide a framework for investigating the pathogen-
esis of DMD in the mdx masticatory system and its
impact on the craniofacial bone. The results of the
presented study will help demonstrate how mastica-
tory muscles adapt to dystrophic changes.
Material and methods
Animals. Mice of the inbred strains C57Bl/10ScSn (con-
trol) and C57/Bl10ScSn-Dmdmdx/J (mdx) were originally
obtained from Harlan Winkelmann (Borchen, Germany)
and Charles River (Sulzfeld, Germany). Both strains were
bred in the Department of Pathophysiology of the Medical
Faculty at the University of Greifswald. Age-matched pairs
of mdx and control animals (each n = 9–10; 100 days old)
of either sex were euthanized using ether. All procedures
were approved by a governmental committee on animal
welfare of the State Government (LALLF M-V/TSD/7221.3-
-2.3-001/09). Tongue, masseter, temporalis and soleus mus-
cles were prepared and shock-frozen in liquid nitrogen for
quantitative reverse transcription PCR, Western blot analy-
ses and immunohistochemistry.
RNA extraction and reverse transcription. Total RNA
was isolated using guanidinium-isothiocyanate (RNeasy
Fibrous Mini Kit, Qiagen, Hilden, Germany) and RNA con-
centration was determined by UV absorbance measure-
ments. An amount of 200 ng total RNA was reverse tran-
scribed using random hexamer primers and the TaqMan
Reverse Transcription Reagents (PE Applied Biosystems,
Weiterstadt, Germany), as described previously [28, 29].
TaqMan RT-PCR. The method was performed as described
previously [30, 31] using a real-time PCR cycler (StepOne
Plus, Applied Biosystems). Gene-specific primers and
probes were purchased from PE Applied Biosystems (cav-1:
Mm00483057_m1; cav-3: Mm01182632_m1; VEGF:
Mm01281449_m1) with each probe having been synthesized
with a fluorescent 5’-reporter dye (FAM: 6-carboxy-fluo-
rescein) and a 3’-quencher dye (TAMRA: 6-carboxy-tetram-
ethyl-rhodamine). All values are given in relation to the
mRNA of 18S rRNA. A ‘no-template control’ with water
was performed parallel to all experiments. Each series of
experiments was performed twice.
Western blot analysis. Muscle tissue samples were mechan-
ically homogenized using the SpeedMill P12 homogenizer
(Analytikjena, Jena, Germany). Total protein extracts
(30 μg) were separated on SDS gels, transferred to nitrocellu-
lose membranes (Schleicher&Schuell) using a tank blotting
system (Gibco-BRL, Germany) and incubated with antibod-
ies against caveolin-1 (polyclonal, Affinity Bioreagents, via
Dianova, Hamburg, Germany, dilution 1:1,000 in PBS con-
taining 5% powdered milk and 0.025% NaN3) or caveolin-3
(monoclonal, BD Biosciences, Heidelberg, Germany, dilu-
tion 1:400 in PBS containing 5% powdered milk and 0.025%
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NaN3) overnight at 4°C. Secondary HRP-conjugated goat
anti-rabbit or goat anti-mouse immunoglobulins (Dako,
Hamburg, Germany) were used at a dilution of 1:5,000. Vi-
sualization and detection of bound antibodies were carried
out using an enhanced chemiluminescence system (Perbio
Science). As control for the specificity of the antibodies,
antigen-preincubated antibodies (1 μg peptide per 1 μg of
antibody) were used in the same way. To assess equal load-
ing of the gel, every membrane was stripped with RestoreTM
Plus Western blot stripping buffer (Perbio Science) and in-
cubated with a monoclonal anti-a-actinin antibody (clone
AT6/172, Upstate, dilution 1:1,000; two hours at room tem-
perature). Quantitative analyses of protein bands from cav-1,
cav-3 and a-actinin in masticatory muscles were carried out
using GelScan 5.2 software (Serva, Germany). MOD (mean
optical density) ± SEM are given in all cases for n = 4 muscle
samples and four independent Western blot analyses.
Immunohistochemistry. Indirect immunohistochemistry was
performed on acetone or methanol/H2O2 fixed cryo-sections
(5 μm; n = 4 different animals) using a polyclonal anti-caveo-
lin-1 antibody (Affinity Bioreagents via Dianova, Hamburg,
Germany, dilution 1:1,000) or a monoclonal mouse anti-cave-
olin-3 antibody (clone 26, BD Biosciences, Heidelberg, Ger-
many, dilution 1:400), as described previously [32]. Staining
was performed following the instructions for the ABC-systems
(Vectastain ABC kit, Vector Laboratories, Burlingame, CA,
USA) either with a biotinylated secondary anti-rabbit antibody
or the M.O.M.-kit (Vector Laboratories). Incubation with the
primary antibodies was done for one hour at room tempera-
ture. Visualization of bound cav-1 and cav-3 antibodies was
done using a New Fuchsine alkaline phosphatase substrate
protocol. Sections were counterstained in hematoxylin and then
cover-slipped. In negative controls, the primary antibody was
replaced by PBS, and PBS used in the same way.
A simultaneous blind test was conducted using identi-
cal staff, equipment and chemicals to determine the level
of antigen. From each section, five digital pictures were tak-
en, at random, of different parts of the tissue (200 × mag-
nification; 3CCD color camera; Hitachi HV-C20M; Hita-
chi Denshi Ltd, Japan, and Axiolab, Carl Zeiss, Göttingen,
Germany). For standardization of the measurement in each
picture, the optical density of white background color was
attuned to 250. For all sections, we assessed the MOD and
the quantity of pixels that had a positive reaction for cav-1
and cav-3 using KSRun software (imaging system KS400,
release 3.0; Zeiss, Vision GmbH, Munich, Germany) or
ImageJ 1.42 for Windows (http://rsbweb.nih.gov/ij/).
Statistical analysis. All statistical analyses were performed
using SigmaPlot software (Systat Software, Inc., San Jose,
CA, USA). Statistical analyses were made using Student’s
unpaired t-test. Data is given as means ± SEM; p < 0.05
was considered statistically significant.
Results
Expression of cav-1, cav-3 and VEGF
in masticatory muscles of mdx mice
Quantitative TaqMan RT-PCR performed on masti-
catory muscle tissue samples and soleus muscle re-
vealed the presence of cav-1, cav-3 and VEGF in mdx
and control mice. Since we observed no differences
in gene expression between male and female animals,
the data from both sexes was combined.
The mRNA expression of cav-1 was 2.8-fold in-
creased in dystrophic masseter muscle compared to
controls (control vs. mdx: 39 ± 4 vs. 110 ± 19; **p =
= 0.0103). The mRNA expression of cav-3 and
VEGF remained unchanged in mdx masseter mus-
cle (Figure 1). In temporal and tongue muscles, no
significant differences were observed for all three
tested transcripts between control and mdx mice. In
contrast, the soleus muscle from mdx mice showed
significantly lower transcript levels of VEGF (con-
trol vs. mdx: 571 ± 94 vs. 291 ± 45; *p = 0.0234).
The VEGF mRNA level reached about 70–80%
compared to those in non-dystrophic control mice
(Figure 1), while cav-3 expression significantly in-
creased (1.5-fold; control vs. mdx: 218 ± 13 vs. 327 ±
± 59; *p = 0.0496) and cav-1 expression remained
unchanged.
Western blot analysis allowed us to semi-quan-
tify cav-1 and cav-3 proteins (Figure 2). Single im-
munoreactive bands of approximately 22 and
18 kDa, respectively, were detected. These bands
agreed with the expected molecular weights of cav-
1 and cav-3 (Figure 2A). Using antigen pre-incu-
bated antibodies, no specific immunoreactive bands
were detected. Quantitative evaluation of the West-
ern blots showed slightly increased levels of cav-1 pro-
tein in all tested muscles of mdx mice (mean ± SEM;
control vs. mdx: masseter, 1.24 ± 0.25 vs. 1.21 ± 0.12;
temporalis, 1.38 ± 0.19 vs. 1.46 ± 0.17; tongue, 0.74 ±
± 0.18 vs. 0.89 ± 0.18; soleus, 0.82 ± 0.18 vs. 0.95 ±
± 0.21). The protein levels were 106–119% of those of
control mice (Figure 2B). Quantitative evaluation of
cav-3 Western blots showed a tendency towards in-
creased levels between mdx and control mice in
tongue, temporal and soleus muscle (mean ± SEM;
control vs. mdx: temporalis, 1.0 ± 0.35 vs. 1.51 ± 0.37;
tongue, 1.13 ± 0.38 vs. 1.49 ± 0.28; soleus, 1.08 ±
± 0.02 vs. 1.83 ± 0.22). A 1.3- to 1.7-fold increase in
protein expression in dystrophic muscles was detect-
ed (Figure 2C). Only in mdx masseter muscle were
reduced protein levels detected compared to control
muscle (mean ± SEM; control vs. mdx: 1.69 ± 0.23
vs. 1.37 ± 0.41).
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Cellular localization of cav-1 and cav-3
in masticatory muscles
Using immunohistochemistry with the polyclonal an-
tibody against cav-1, we found a strong staining of
endothelial and satellite cells in muscle cross-sections
of both mouse strains (Figure 3A). Computerized
analysis of the staining intensity (optical density) is
shown in Figure 3B. We found a significant increase
in cav-1 protein expression in the masseter and tem-
poral muscles of mdx mice compared to controls (mas-
seter: control vs. mdx = 536 ± 64 vs. 966 ± 149; *p =
= 0.017; temporal: control vs. mdx = 420 ± 56 vs. 696 ±
± 115; *p = 0.046). In addition, there were no signifi-
cant differences in cav-1 protein expression in tongue
and soleus muscle between control and mdx mice.
Immunohistochemical staining of muscle cross-
-sections showed the presence of cav-3 proteins in
Figure 1. Quantification of cav-1, cav-3 and VEGF mRNA
levels in 100 day old control (grey columns) and mdx (black
columns) mice. Levels of mRNA were determined using RNA
preparations from masseter, temporal and soleus muscles as
well as the tongue. The mRNA levels of all tested genes are
given in relation to that of 18S rRNA. Means ± SEM are given
in all cases for n = 9–10 samples. Stars indicate significant
differences: *p < 0.05; **p < 0.01, unpaired t-test
Figure 2. Detection of cav-1 and cav-3 in masticatory and
soleus muscles. (A) Representative Western blots of cav-1
and cav-3 in masseter, temporal and soleus muscles as well
as tongue from control and mdx mice. The membranes
were probed with a polyclonal antibody against cav-1 and
a-monoclonal antibody against cav-3. A monoclonal
antibody was used to detect a-actinin serving as an internal
control. (B) Quantitative analyses of cav-1 Western blots as
shown in A. (C) Quantitative analyses of cav-3 Western
blots as shown in A. Protein bands attributed to cav-1,
cav-3 and a-actinin were evaluated using GelScan 5.2
software (Serva, Germany). Mean optical densities (MOD)
± SEM of control and mdx mice are given in all cases for
four independent experiments
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the sarcolemma of control and mdx muscle fibers
(Figure 4A). The cav-3 antigen expression deter-
mined by densitometric analyses of the immunohis-
tochemical stained sections was 1.5-fold increased
in the masseter muscle, and 1.3-fold in the tongue
and soleus muscles, of mdx mice compared to the
levels of cav-3 in control mice (MOD, masseter: con-
trol vs. mdx = 1,876 ± 144 vs. 2,876 ± 321; p =
= 0.013; tongue: control vs. mdx = 2,711 ± 165 vs.
3,520 ± 217; p = 0.0084; soleus: control vs. mdx =
= 2,577 ± 250 vs. 3,303 ± 189; p = 0.034). No sig-
nificant differences in cav-3 protein expression were
found in the temporal muscle of either experimen-
tal group (Figure 4B).
All sections incubated with PBS instead of the pri-
mary antibody were devoid of any positive reaction.
Discussion
The involvement of caveolae and caveolins in the
pathogenesis of Duchenne muscular dystrophy has
been suggested, because: (i) cav-3 has been found to
be localized to the sarcolemma, which coincides with
the distribution of dystrophin and co-fractionates with
members of the dystrophin complex [11]; (ii) skeletal
muscle caveolae have been found to undergo charac-
teristic changes in size and distribution in patients with
DMD [19]; and (iii) transgenic overexpression of cav-3
induces a phenotype similar to DMD [15].
Furthermore, caveolae and caveolins are clearly
important to vascular function, angiogenesis and dur-
ing inflammation [12]. It has recently been shown that
mdx orofacial muscles, e.g. masseter and temporal,
were severely affected by dystrophin deficiency, while
mdx tongue muscle was partially spared. These chang-
Figure 3. (A) Immunohistochemical staining of cav-1 in
cryo-sections of masseter muscle samples from control
and mdx mice at two different magnifications. Cav-1
staining is in red; counterstaining of the nuclei with
hemalaun (blue). (B) Densitometric analysis of the cav-1
staining intensity. The mean optical densities (MOD) ±
± SEM of control and mdx mice are given in all cases.
Stars indicate significant differences: *p < 0.05; ***p <
0.005, unpaired t-test
Figure 4. (A) Immunohistochemical staining of cav-3 in
cryo-sections of masseter muscle samples from control
and mdx mice at two different magnifications. Cav-3
staining is in red; counterstaining of the nuclei with
hemalaun (blue). (B) Densitometric analysis of the cav-3
staining intensity. The mean optical densities (MOD)
± SEM of control and mdx mice are given in all cases.
Stars indicate significant differences: ***p < 0.005,
unpaired t-test
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es were found to be accompanied by intensive regen-
eration, with numerous inflammatory foci and new
vessel formations [27].
In our study, we analyzed the expression of ca-
veolin-1 and -3 as well as VEGF in the masticatory
muscles of the animal model of DMD, the mdx
mice. With regard to the expression of caveolin-3,
the tested masticatory muscles showed significant
differences on the protein level between mdx and
control mice. Our results on masticatory muscles
do not differ from those using hindlimb muscles,
because in dystrophin-negative soleus muscle, an
increase in the cav-3 expression was also observed.
The increased abundance of cav-3 in the mastica-
tory muscles and soleus of 100 day old mdx mice is
consistent with previous reports demonstrating that
cav-3 is upregulated in mdx tibialis anterior [22],
in mdx extensor digitorum longus [33], in the mus-
cles of dystrophic chickens [34] and in the quadri-
ceps of DMD patients [21].
However, the mechanisms by which cav-3 is in-
volved in the mdx/DMD dystrophin deficiency re-
mains unclear. New observations suggest that cav-3
expression is necessary for transient receptor poten-
tial cation channel canonical 1 (TRPC1) localiza-
tion. TRPC1 and cav-3 are co-localized and co-im-
munoprecipitated [35]. TRPC1 is a stretch-activat-
ed Ca2+ channel and seems to play a role in Ca2+
induced membrane damage in mdx/DMD skeletal
muscle fibers [36].
It seems possible that as well as cav-3, cav-1 could
also play an important role in the pathogenesis of
DMD, because cav-1 knockout mice displayed numer-
ous skeletal muscle abnormalities, including tubular
aggregates [37]. Cav-1 plays an essential role in the
regulation of cell proliferation.
It has recently been shown that skeletal muscle
fibers from fetuses at late gestation stage, and from
newborns, express cav-1, whereas adult samples do
not show any immunoreaction for caveolin-1 [38]. The
expression of cav-1 in the skeletal muscle could also
be a marker for muscle regeneration as well as for
inflammation. In the tested dystrophic masticatory
muscles, we found an increase in the expression of
cav-1. Because both protein and mRNA were extract-
ed from the whole muscle sample containing muscle
fibers, blood vessels and connective tissue, it seems
possible that the increased concentration of cav-1 is
due to: (i) formation of new blood vessels during re-
generation: the numerous inflammatory foci found
in mdx masticatory and soleus muscles are associat-
ed with new vessel formation and leukocyte accumu-
lation [27]; (ii) by fibroblasts, which are responsible
for increased collagen and connective tissue content
in mdx muscles [27, 39, 40]; and (iii) by the physio-
logical abundance of adipocytes. It is known that cav-1
is mainly expressed in adipocytes, smooth muscle cells,
fibroblasts, and endothelial cells [5, 41, 42]. Unlike
the other masticatory muscles, in the tongue we did
not find changes in the level of cav-1. This could ex-
plain our earlier results which showed a virtually un-
affected tongue muscle, with absence of inflamma-
tion and collagen accumulation [27].
Angiogenesis is necessary for muscle regeneration.
The proliferation of capillary endothelial cells is stim-
ulated by VEGF, a critical regulating factor in angio-
genesis [43]. In DMD patients, increased VEGF se-
rum levels have been detected [44]. On the other hand,
mdx mice treated with recombinant VEGF have
shown increased forelimb strength and regenerating
fibers and reduced necrotic areas [45]. In our study,
unchanged or reduced mRNA amounts of VEGF
were found in the tested dystrophic muscles compared
to controls.
It is worth emphasizing that we analyzed VEGF
only on the transcriptional level, and our results for
VEGF should be verified on the level of protein ex-
pression. However, there is clear evidence of a close
relationship between VEGF and caveolins. VEGFR-2
has been found to be localized in caveolae and cav-1
has been shown to reduce VEGF-stimulated angio-
genesis in vivo, demonstrating direct cav-1 regulation
of angiogenesis [12, 46].
To sum up, in the masticatory muscles of mdx mice
we found an increase in cav-1 and cav-3 expression,
whereas the amount of VEGF seemed to be un-
changed. The differences in the cav-1 and cav-3 ex-
pression between the studied muscles confirm previ-
ous observations that muscles in mdx mice are un-
equally affected by dystrophin deficiency. We conclud-
ed that dystrophic masticatory muscles of 100 day old
mdx mice showed complex muscle adaptation during
the muscle regeneration process.
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